Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

Lilly Will Invest $350 Million in China Diabetes Cartridge Facility

publication date: Nov 14, 2013
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Lilly announced it will spend $350 million in China to increase its production of insulin cartridges. The company emphasized that China is home to the world’s largest population of diabetics – which numbers almost 100 million now and is expected to grow as China’s population adopts western lifestyles. The China investment is part of a larger $1 billion building projects that Lilly has announced since the beginning of the year to increase diabetes drug capacity. More details....

Stock Symbol: (NYSE: LLY)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...